Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
Organisation › Details

Omeicos Ophthalmics Inc.

OMEICOS Therapeutics is a spin-off company from the Max Delbrueck Center for Molecular Medicine (MDC) in Berlin. The company has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids that have the potential to treat inflammatory, cardiovascular and other diseases. Epoxyeicosanoids, as a newly described class of bioactive lipid mediators, activate cell type-specific endogenous pathways that promote organ and tissue protection. OMEICOS’ small molecules are orally available and show improved biological activity and pharmacokinetic properties compared to their natural counterparts. OMEICOS’ technology is based on ground-breaking scientific results in the field of omega-3 fatty acid metabolism and physiology obtained by the companies’ founders, Dr. Wolf-Hagen Schunck, Prof. John. R. Falck, Prof. Dominik Mueller and Dr. Robert Fischer. The companies’ research activities are supported by a grant from the German Ministry of Education and Research (BMBF). *

 

Period Start 2018-04-01 established (approx)
  Group Omeicos (Group)
Product Industry ophthalmic
Person Person Gebauer, Alexander (Omeicos 201804– Executive Board Member + CEO of Omeicos Ophthalmics before Sun Pharma + Ranbaxy)
     
Region Region Boston, MA
  Country United States (USA)
  City n. a. Boston, MA
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Omeicos Therapeutics GmbH. (4/27/18). "Press Release: Alexander Gebauer Joins Executive Board of Omeicos Therapeutics and Named CEO and Chairman of Omeicos Ophthalmics". Berlin & Boston, MA.
     
   
Record changed: 2020-04-26

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Omeicos (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80




» top